-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target

Benzinga·03/28/2025 11:23:07
Listen to the news
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $11.5 price target.